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Abstract
FR901533 (1, also known as WS79089B), WS79089A (2), and WS79089C (3) are polycyclic
aromatic natural products with promising inhibitory activity to endothelin-converting enzymes.
In this work, we isolated five tridecaketide products from Streptosporangium roseum No. 79089,
including 1-3, benaphthamycin (4) and a novel FR901533 analogue (5). The structure of 5 was
characterized based on spectroscopic data. Compared to the major product 2, the new compound
5 has an additional hydroxyl group at C-12 and an extra methyl group at the 13-OH. The
configuration of C-19 of these compounds was determined to be R using Mosher's method. A
putative biosynthetic gene cluster for compounds 1-5 was discovered by analyzing the genome
of S. roseum No. 79089. This 38.6-kb gene cluster contains 38 open reading frames, including
a minimal polyketide synthase (wsaA-C), an aromatase (wsaD), three cyclases (wsaE, F and W)
and a series of tailoring enzymes such as monooxygenases (wsaO1-O7) and methyltransferases
(wsaM1 and M2). Disruption of the ketosynthase gene (wsaA) in this gene cluster abolished the
production of 1-5, confirming that this gene cluster is indeed responsible for the biosynthesis
of 1-5. A type II polyketide biosynthetic pathway was proposed for this group of natural
endothelin-converting enzyme inhibitors.
Key points
•

Five aromatic tridecaketides were isolated from Streptosporangium roseum No.
79089.

•

A novel FR901533 analogue, 12-hydroxy-13-O-methyl-WS79089A, was
characterized.

•

The absolute configuration of C-19 of FR901533 and analogues was determined.

•

The biosynthetic gene cluster of FR901533 and analogues was discovered.
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Introduction
Endothelin (ET) is a potent vasoconstrictor peptide released from renal endothelial and other
cells, which exists in three isoforms, ET-1, ET-2, and ET-3 (Davenport et al. 2016). They are
21-amino acid peptides, with ET-1 being the most abundant isoform. ETs are involved in
maintaining the balance between vasoconstriction and vasodilation in the normal human
cardiovascular system. However, overexpression of ETs can contribute to high blood pressure,
which can hurt heart, general circulation and brain (Coelho et al. 2018), and leads to cancer
(Bagnato et al. 2008), pain mediation (Smith et al. 2014), cerebral vasospasm (Cheng et al.
2018) and other cardiovascular disorders.
Physiologically active ETs are formed from big ETs by endothelin-converting enzymes
(ECEs) through the selective cleavage at the Trp21-Val/Ile22 peptide bond (Johnson et al. 1999).
Two major forms of ECE, including ECE-1 and ECE-2, have been reported (Emoto and
Yanagisawa 1995; Kaburagi et al. 1999). ECE-1 is the enzyme primarily responsible for the
synthesis of active ET-1 (Whyteside et al. 2014). ET-1 plays a critical role in cardiovascular
diseases (CVDs) such as hypertension, pulmonary hypertension, atherosclerosis, congestive
heart failure, and myocardial infarction (Dhaun and Webb 2019; Rodríguez-Pascual et al.
2011). Under these pathophysiological conditions, circulating ET levels in plasma, urine or
cerebrospinal fluid are elevated (Löffler 2000). Therefore, inhibition of the ET system may have
significant potential for the development of new CVD therapeutics. Two common approaches
are used to inhibit ET, including blockade of the ET receptors and inhibition of ECE-1 (Hitzerd
et al. 2020; Miyagawa and Emoto 2014). Studies in animal disease models suggested that ECE1 inhibitors may be used in the treatment of pulmonary hypertension, cardiac hypertrophy and
failure, myocardial infraction, restenosis, and acute renal failure (De Lombaert et al. 2000;
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Doggrell 2004).
About a half of approved small-molecule therapeutics are either natural products or
directly derived from natural products (Newman and Cragg 2020). FR901533 (1, also known
as WS79089B), WS79089A (2), WS79089C (3) and benaphthamycin (4) shown in Fig. 1 are
dihydrobenzo[]naphthacenequinone natural products produced by actinomycetes (Ritzau et al.
1997; Tsurumi et al. 1994). 1-3 have shown selective inhibitory activity to ECE, with IC50
values of 0.14, 0.73 and 3.42 µM, respectively. Among these compounds, 1 is three times more
potent than the well-known ECE inhibitor phosphoramidon (IC50 = 0.49 µM). Furthermore, 13 have also shown great safety profiles. Acute toxicity studies in mice revealed that their LD50
values were higher than 100 mg/kg, and did not have any toxicity until day 14 (Tsurumi et al.
1994). Further studies showed that 1 acts as a competitive inhibitor of ECE, with a Ki value of
8.9  10-8 M (Tsurumi et al. 1995). Animal studies revealed that 1 can protect the development
of right ventricular overload and reduce the degree of medial thickening of pulmonary arteries
in rats (Takahashi et al. 1998). It reduced the conversion of big ET-1 to ET-1 in post-myocardial
infarction rats and improved some parameters of cardiac remodeling early post-myocardial
infarction (Martin et al. 2000). 1 was reported to decrease the blood pressure in apolipoprotein
E (apoE)-deficient mice fed with a Western-type fat diet (Martínez-Miguel et al. 2009) and
calcitriol-treated rats (Martínez-Miguel et al. 2014). Phenylephrine induces the expression of
ET-1 in rat cardiac myocytes and increases the conversion of big ET-1 to ET-1. A study found
that 1, as a specific ECE-1 inhibitor, can inhibit the phenylephrine-stimulated increase in protein
synthesis rate by 45% (Kaburagi et al. 1999). 1 also decreased plasma renin activity, as well as
the levels of plasma atrial natriuretic peptide, angiotensin II, and aldosterone in beagle dogs
(Wada et al. 1999). Another study in dogs revealed that 1 decreased pulmonary capillary wedge
pressure and increased cardiac output. This compound prevented the reduction of urine flow
rate and urinary sodium excretion in association with an increase in the glomerular filtration
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rate and renal plasma flow, and significantly suppressed the elevation of plasma atrial natriuretic
peptide and aldosterone levels, which is an established prognostic factor in congestive heart
failure. These results indicate that chronic ECE inhibition has potential for the treatment of
congestive heart failure, not only on hemodynamics but also in the prevention of fluid retention
(Wada et al. 2002). Therefore, this family of compounds represent promising lead compounds
for the development of new CVD therapeutics.
In continuation of our effort to search for new natural product for drug discovery, a new
analogue (5) of FR901533 was isolated from Streptosporangium roseum No. 79089, along with
the known compounds 1-4. The C-19 configuration was determined using the Mosher method.
A putative biosynthetic gene cluster was discovered from the genome of S. roseum No. 79089,
and its involvement in the biosynthesis of 1-5 was confirmed through gene disruption.
Fig. 1

Materıals and methods
General equipment
Products were analyzed and purified on an Agilent 1200 HPLC instrument with an Agilent
Eclipse XDB-C18 column (5 μm, 250 mm × 4.6 mm). The samples were eluted with
acetonitrile-water (5:95 to 100:0, v/v) at a flow rate of 1 mL/min for 30 min and detected at 460
nm. ESI-MS spectra were obtained on an Agilent 6130 single quadrupole LC-MS in the
negative mode. 1D and 2D NMR spectra were recorded in deuterated dimethyl sulfoxide
(DMSO-d6) on a JEOL ECX-300 NMR instrument (300 MHz for 1H NMR and 75 MHz for 13C
NMR) or a Bruker Avance III HD Ascend-500 NMR instrument (500 MHz for 1H NMR and
125 MHz for

13

C NMR) in the Department of Chemistry and Biochemistry, Utah State

University. The chemical shift (δ) values are given in parts per million (ppm). The coupling
constants (J values) are reported in hertz (Hz).
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Strains and vectors
S. roseum No. 79089 (NRRL 2505) was obtained from the USDA Agricultural Research
Service Culture Collection. Escherichia coli XL-1 Blue (Stratagene) and the pJET1.2 cloning
vector (Thermo Fisher) were used for routine subcloning. E. coli ET12567 (pUZ8002) and
pKC1139 vector were used for the gene disruption experiments.
Media and culture conditions
S. roseum No. 79089 and its mutants were maintained on YM (yeast extract-malt extract) agar
plates at 28C. E. coli strains were routinely cultured in Luria-Bertani (LB) broth at 37C. MS
(mannitol soya flour), ISP4 (international Streptomyces project medium 4), and TSB (tryptic
soy broth) media were used in the conjugation experiments. Ampicillin (50 g/mL) and
apramycin (50 g/mL) were added to the media appropriately for the cloning or conjugation.
Extraction, analysis and purification of compounds
S. roseum No. 79089 and its disruption mutant were grown on YM agar plates (with or without
apramycin). The cultures were extracted three times with an equal volume of methanol. The
extracts were then dried under reduced pressure and re-dissolved in methanol for LC-MS
analysis. To isolate compounds 2-5, the cultivation of wild type S. roseum No. 79089 was scaled
up to 1 L. The plates were maintained at 28C. After 7 days, the culture was extracted with 1 L
of methanol three times. The extract was dried under reduced pressure. The compounds (2, 3,
4 and 5) were purified by HPLC on a C18 reversed phase column, eluted with acetonitrile-water
(5:95 to 100:0, v/v) at a flow rate of 1 mL/min over 30 min, yielding 29.8 mg of 2, 4.3 mg of 3,
3.5 mg of 4, and 5.3 mg of 5.
Preparation of (S)-MTPA (2S) and (R)-MTPA (2R) esters
1 mg of 2 was transferred into one clean and completely dry NMR tube. Anhydrous pyridined5 (0.4 mL) and R-(+)--methoxy--(trifluoromethyl) phenylacetyl chloride [(R)-MTPA-Cl]
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were added to the NMR tube quickly, and the NMR tube was shaken carefully to evenly mix
the sample with (R)-MTPA-Cl. The reaction mixture was allowed to stand at room temperature
for 12 hours to yield the corresponding (S)-MTPA ester 2S. Similarly, 1 mg of 2 was reacted
with (S)-MTPA-Cl to yield the corresponding (R)-MTPA ester 2R. The 1H NMR spectra of 2S
and 2R were collected on a Bruker Avance III HD Ascend-500 NMR instrument. The Δδ
(δ2S−δ2R) values for proton signals near C-19 were calculated.
Analysis of the genome of S. roseum and annotation of the putative wsa biosynthetic gene
cluster
The genome of S. roseum No. 79089 (GenBank accession number CP001814) has been
previously reported (Nolan et al. 2010). Analysis of the sequenced genome was performed with
RAST (rapid annotation using subsystem technology) (Overbeek et al. 2013). The wsa gene
cluster was annotated with FramePlot (Ishikawa and Hotta 1999).
Plasmid construction for the disruption of wsaA in S. roseum No. 79089
To find out whether the discovered gene cluster is involved in the biosynthesis of 1-5, a 732-bp
fragment of the putative ketosynthase gene wsaA was amplified from the genomic DNA of S.
roseum No. 79089 with a 30-cycle PCR program (15 s at 98C, 15 s at 62C, and 30 s at 72C).
The

two

primers

were

used,

including

AAGAATTCGTAACATCACGCTGTTCGAC-3')

and

2505-KS-KO-F-EcoRI

(5'-

2505-KS-KO-R-HindIII

(5'-

AAAAGCTTTGAGACCGGTCATGTGGTAG-3'). The PCR product was ligated into the
pJET1.2 vector. The ligation product was transferred into E. coli XL1-Blue. Correct
transformants were selected by ampicillin resistance. Colonies were picked into 5 mL of LB
broth with 50 g/mL ampicillin, which were grown at 37C overnight. Plasmids were extracted
and then digested with EcoRI and HindIII. The correct plasmid was named as pSW129. After
sequencing, the wsaA fragment was excised from pSW129 and ligated into pKC1139 between
EcoRI and HindIII to afford pSW130.
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Conjugation and verification of the wsaA-disrupted mutant of S. roseum No. 79089
The gene disruption plasmid pSW130 was introduced into E. coli ET12567 (pUZ8002) through
chemical transformation. It was then introduced into S. roseum No. 79089 by E. coli–
Streptomyces conjugation, following the previously reported procedure (Bierman et al. 1992;
Shao et al. 2012). The resulting E. coli strain (E. coli ET12567 (pUZ8002)/pSW130) was used
as donor and S. roseum No. 79089 was the acceptor. The positive colonies were picked into
TSB medium with 50 g/mL of apramycin after 20 days of culture on MS plates. The colonies
were grown in TSB medium at 28C and 250 rpm for 7 days and 50 µL of the culture was
spread on ISP4 plates with 50 g/mL of apramycin. Colonies showing up at 37C were
considered as the recombination strain, which was further cultured on YM plate with 50 g/mL
apramycin at 28C for product check. The mutants were confirmed by PCR analysis with a set
of pKC1139- and genome-specific primers, including M13-47, RV-M, 2505-KS-check-1 (5'AGTACGTGGCCGAGCACTA-3') and

2505-KS-check-2 (5'-

TGAGCACGGAGTCGATCG-3') using a 30-cycle PCR program (30 s at 98C, 30 s at 58C,
and 60 s at 72C).

Results
Detection of five major dihydrobenzo[]naphthacenequinone compounds in the culture
of S. roseum NRRL 2505
S. roseum No. 79089 was grown in YM agar and analyzed by LC-MS. As shown in trace i of
Fig. 2a, five major products were detected at 460 nm. These compounds had a similar maximum
UV absorption at ~460 nm, suggesting that they are structurally related analogues. ESI-MS
spectra (Figs. 2b-2f) of 1-5 showed the corresponding quasimolecular ion [M-H]- at m/z 505.2,
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487.1, 529.3, 503.0 and 517.2, indicating that the molecular weights of 1-5 are 506, 488, 530,
504 and 518, respectively.
These compounds were purified and subjected to NMR analysis. The major product 2
has a molecular weight of 488, which is consistent with that of WS79089A previously isolated
from this strain. Its 1H NMR data (Table S1) are in good agreement with those reported
(Tsurumi et al. 1994), confirming that compound 2 is WS79089A. Compound 1 has a molecular
weight of 504, which is 18 mass units larger than 1, suggesting that a water molecule has been
added into the structure of 2. This molecular weight is the same as that of FR901533, also named
WS79089B, a hydrolyzed derivative of 2. Indeed, 2 can be easily converted to 1 in the presence
of 1 N NaOH (Fig. S1), further supporting that 1 is FR901533. Similarly, the structures of 3
and 4 were characterized as WS79089C and benaphthamycin, respectively, by a comparison of
their 1H NMR (Table S1) with literature (Ritzau et al. 1997; Tsurumi et al. 1994).
Fig. 2
Characterization of 5 as 12-hydroxy-13-O-methyl-WS79089A
The molecular weight of 5 was determined to be 518, which is 30 mass units larger than the
major product 2. The 1D and 2D NMR of 5 were collected. The
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C NMR spectrum of 5

revealed 28 carbon signals (Table 1), with one additional methoxy signal at C 61.3 than the
major product 2, suggesting that one of the hydroxyl groups has been methylated. This was
supported by the OCH3 signal at H 3.86 in the 1H NMR (Table 1). The NMR data also revealed
that one aromatic CH has been hydroxylated, indicated by the absence of an aromatic proton
signal and the appearance of a low field aromatic quaternary carbon signal at C 159.0. Overall,
the introduction of a hydroxyl group and a methyl group is consistent with the mass difference
(30 Da) between 2 and 5.
Table 1
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A further comparison of the 1H NMR data of 5 (Table 1) and 2 (Table S1) indicated that
the major difference lies in ring A. The three free aromatic proton signals on ring A of 2 include
two overlapped signals at H 7.71-7.88 that belong to H-10 and H-11 and a dd (doublet of
doublets) H-12 signal at H 7.38 (Table S1). However, there were only two aromatic proton
signals on the same ring of 5, including a doublet at H 7.93 and a doublet at H 7.28 (Table 1).
The coupling constant of these two doublets are 8.6 Hz, indicating that these two protons are
ortho to each other. The signal at H 7.93 was assigned to H-10 due to its HMBC correlation to
C-8 at C 188.0 (Fig. 3). Therefore, the other aromatic proton signal at H 7.28 must belong to
H-11. The presence of H-10 and H-11 indicated that C-12 was hydroxylated. Furthermore, the
HMBC correlation of the newly introduced methoxy signal at H 3.86 to C-13 at C 147.5 (Fig.
3) confirmed that the 13-OH was methylated. Therefore, 5 was identified as 12-hydroxy-13-Omethyl-WS79089A, which is a new compound and was named as WS79089D.
Fig. 3
Determination of the absolute configuration of the C-19 of WS79089A
Compounds 1-5 have a hydroxyl group at C-19. The 19-OH of 1, 2, 4 and 5 is free, while that
of 3 was acetylated (Fig. 1). To find the configuration of this hydroxyl group, we chose the
major product 2 to prepare the Mosher esters. This compound was reacted with R- and S-MTPA
chloride in deuterated pyridine in NMR tubes to afford the corresponding S- and RMTPA ester derivatives, 2S and 2R. The 1H NMR of these MTPA esters were collected. The
Δ ([S−R]) values near C-19 were calculated and are shown in Fig. 4, which revealed that the
absolute configuration of C-19 is R. This is same as C-19 in pradimicin A, whose configuration
was found to be R as well (Napan et al. 2014). Therefore, based on our results, the 19-OH of 2
was determined to be in an  configuration.
Fig. 4
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Discovery of a putative WS79089 (wsa) biosynthetic gene cluster and the proposed
biosynthetic pathway
The structures of 1-5 indicated that they are synthesized through a type II polyketide
biosynthetic pathway. By searching the reported genomic sequence of S. roseum No. 79089 in
the NCBI GenBank, a putative type II PKS gene cluster for the biosynthesis of WS79089A
(wsa) and analogues was located in this strain. As shown in Fig. 5a, this 38.6 kb wsa gene
cluster contains 38 open reading frames (orfs). Their putative functions were predicted based
on BLAST analysis of the corresponding amino acid sequences (Table 2). This gene cluster has
3 regulatory genes (wsaR1, R2 and R3), a minimal PKS (wsaA, B and C), an aromatase (wsaD),
three cyclases (wsaE, F and W), three ketoreductases (wsaG, T and V), two methyltransferases
(wsaM1 and M2), and a number of other tailoring enzymes such as monooxygenases (wsaO1O6) and oxidoreductases (wsaJ and wsaH1-H5). There are also hypothetical proteins (wsaU1U3), asparagine synthetase (wsaN), and nitroreductase (wsaP) that might not be involved in the
biosynthesis of 1-5.
Fig. 5
The wsa minimal PKS, including WsaA (ketosynthase), WsaB (chain length factor) and
WsaC (acyl carrier protein), is proposed to generate a nascent 26-carbon poly-β-ketone
intermediate 6 by condensing acetyl-CoA with 12 units of malonyl-CoA. The ketone group at
C-11 is then reduced by a ketoreductase (WsaV or WsaT) to a hydroxyl to yield 7. The hydroxyl
group will be removed when ring A and B are cyclized by the aromatase WsaD, which leads to
a free proton at C-11 in the intermediate 8 and the final structure of 1-5. It was reported that in
the biosynthesis of pradimicin A, a pentangular aromatic polyketide, the closure of rings C-E
requires synergistic actions of two cyclases and a ring B monooxygenase (Zhan et al. 2008).
We proposed that a similar approach is also adopted in the biosynthetic pathway of 1-5. WsaE
and WsaF will work with WsaO3, a homolog of the pradimicin ring B monooxygenase PdmH,
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to yield the pentangular intermediate 9. A ketoreductase, WsaV or WsaT reduces the 25-ketone
to a hydroxyl group to afford 10. Another ketoreductase, WsaG, will reduce the 19-ketone of
10 to a hydroxyl group to generate 11. One of the monooxygenases will introduce a hydroxyl
group to C-5 to yield 12. Finally, methylation of the 17-OH of 12 will lead to the formation of
1. Closure of ring F by the putative cyclase WsaW can convert 1 to the major product 2.
Compounds 3 and 4 can be formed from 2 by acetylation at the 19-OH and hydroxylation at C24, respectively. 2 can also be hydroxylated at C-12 and methylated at the 13-OH to give rise
to 5. The proposed biosynthetic pathway of 1-5 is shown in Fig. 5b. The order of the tailoring
steps is to be determined.
Table 2
Confirmation of the involvement of the wsa gene cluster in WA79089 biosynthesis
To find out whether this type II polyketide biosynthetic gene cluster is involved in the
biosynthesis of 1 and its analogues, we conducted a gene disruption experiment. The
ketosynthase catalyzes the decarboxylative condensation of the starter unit (acetyl-CoA) with
the extender unit (malonyl-CoA), and thus plays an essential role in the biosynthetic process.
We cloned a 732-bp gene fragment from the putative ketosynthase gene wsaA into pKC1139,
yielding the disruption plasmid pSW130 (Fig. 6a). This plasmid was transferred into S. roseum
No. 79089 through E. coli ET12567-mediated conjugation. After integration of the plasmid
integrated into the genome, the recombination mutant was selected by apramycin resistance and
regrown in YM with apramycin for extraction of the genomic DNA. The disruption of wsaA
was verified by PCR. When primers 1 and 2 were used, a 1.5-kb fragment was amplified from
the wild type, but was not obtained from the mutant due to the insertion of a large plasmid
(pSW130) into the genome (Fig. 6b). When primers 1 and M13-47 were used, a 1.1-kb PCR
product was obtained. This fragment could not be amplified from the wild type due to the use
of the vector-specific primer M13-47 (Fig. 6b). Similarly, when primers 2 and RV-M were used,
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the expected 1.09-kb fragment was amplified from the mutant, but not the wild type (Fig. 6b).
All these results confirmed that the wsaA gene of S. roseum No. 79089 was successfully
disrupted. The correct wsaA-disrupted mutant was grown in YM supplemented with apramycin
and the extract was analyzed by HPLC. As shown in trace ii of Fig. 2a, the production of 1-5
was abolished in this mutant, confirming that WsaA is essential for the production of these
compounds in S. roseum No. 79089. Therefore, the wsa gene cluster was confirmed to be truly
responsible for the biosynthesis of 1-5.
Fig. 6

Discussion
Natural products are a rich source of bioactive molecules, such as penicillin (antimicrobial),
tetracycline (antimicrobial), paclitaxel (anticancer) and lovastatin (anticholesterol). Polyketides
are a group of structurally and functionally diverse natural products, including 1-5 studied in
this work. The main polyketide chain for these polycyclic aromatic compounds contains 26
carbons, and thus are among the longest polyketide natural products that have been discovered
in nature. Several known long aromatic polyketides have been previously reported to possess
interesting biological activities, such as pradimicins (antifungal and antiviral) (Nakagawa et al.
2013), benastatins (antibacterial and glutathione S-transferase inhibitory) (Jiang et al. 2020),
and fredericamycins (antitumor) (Kotha et al. 2019).
1-5 belong to the group of tridecaketides. Few tridecaketides have been previously
reported. For example, accramycin A is an aromatic tridecaketide natural product isolated from
Streptomyces sp. MA37. This compound showed antibacterial activity against Group
B Streptococcus, with a minimum inhibitory concentration (MIC) of 27 µg/mL (Maglangit et
al. 2019). In addition to aromatic tridecaketides, linear polyene tridecaketides have also been
reported. For instance, mycenaaurin A is a pigment from Mycena aurantiomarginata, which
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consists of a tridecaketide backbone connected with two amino acid moieties. It also showed
antibacterial activity against Bacillus pumilus (Jaeger and Spiteller 2010). 1-3 are specific
inhibitors of ECE. 2 is identical to 1 except that its ring F is closed. It can be easily converted
to 1 under alkaline conditions (Fig. S1). 4 was co-isolated with 2 from Streptomyces sp. HKI0057. It showed moderate antibacterial activity against Gram-positive bacteria such as Bacillus
subtilis. This compound also displayed cytopathic effect against animal cells such as K-562
human leukemia cells (Ritzau et al. 1997). 4 is the 24-hydroxylated derivative of 2. This is the
first time this compound was isolated from S. roseum No. 79089. Furthermore, 5 was isolated
from S. roseum No. 79089 and structurally characterized as a new member of the WS79089A
family. This new compound is also an analogue of 2, with structural variations at C-12 and C13. Specifically, it is derived from 2 by the 12-hydroxylation and 13-O-methylation, attributing
to the diverse tailoring enzymes in the wsa gene cluster. Isolation of 5 from S. roseum No.
79089 provides a new compound for testing of the ECE inhibitory activity.
1-5 contain a hydroxyl group at C-19. The configuration of C-19 of the major metabolite
2 was determined to be R using the Mosher method, indicating that there is a  hydroxyl group
at this position. Because of the same biosynthetic origin, it is believed that this is also the case
for 1 and 3-5. The configuration of C-19 in 1-5 is same as that reported for hexaricin A, which
was determined to be R based on circular dichroism spectrum (Tian et al. 2016). Pradimicins
also have a hydroxyl group at this position. We have previously determined the configuration
of C-19 of pradimicins using a similar method (Napan et al. 2014). It was found that this carbon
also has a R configuration, meaning that the 19-OH in pradimicins is in a  configuration. This
hydroxyl group was introduced by a dedicated cytochrome P450 (CYP) hydroxylase (Napan et
al. 2014). However, there are no putative CYP enzymes in this gene cluster (Table 2). Instead,
we propose that the 19-OH is formed through the reduction of the 19-ketone group by a
dedicated ketoreductase. PdmG was previously found to catalyze the reduction of the 19-ketone
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to a hydroxyl group. This 19-OH is likely to be removed by dehydration to yield a double bond,
which is then reduced to afford a single bond between C-19 and C-20, as seen in the pradimicin
biosynthetic intermediate G-2A (Zhan et al. 2008). BLAST analysis revealed that WsaG is
homologous to PdmG, with 56% identity and 74% similarity. Therefore, it is reasonable to
propose that WsaG is the enzyme responsible for reducing the ketone group to hydroxyl at C19.
The wsa gene cluster is highly similar to that reported for hexaricins in
Streptosporangium sp. CGMCC 4.7309 (Tian et al. 2016). The involvement of this gene cluster
in the biosynthesis of 1-5 was confirmed through targeted disruption of the wsaA gene (Fig. 6),
which encodes a ketosynthase. There are three putative transcriptional regulatory genes in the
wsa gene cluster, including wsaR1, R2 and R3. While wsaR2 sits inside the gene cluster, wsaR1
and wsaR3 are at the two ends. The sequence of wsaR1 is similar to acnR, a tet regulatory gene
found in the actinomycin D biosynthetic pathway from marine-derived Streptomyces
costaricanus SCSIO ZS0073 (Liu et al. 2019). Based on the sequence homology, the other two
regulatory genes are proposed to be a TenA family transcriptional regulator and SARP family
transcriptional regulator, respectively. These two regulatory genes correspond to Hex17 and
Hex1 reported in the hex gene cluster. Manipulation of regulatory genes in natural product
biosynthetic pathways is a useful approach to enhance the yields of selected products (Fidan et
al. 2019; Lu et al. 2017; Sun et al. 2018). Therefore, they are interesting targets to identify and
engineer. The minimal PKS, consisting of wsaA, wsaB and wsaC, are homologous to PdmA, B
and C in pradimicin biosynthesis, with 70%-86% similarities (Table 2). PdmA, B and C were
previously characterized as the minimal PKS for pradimicin biosynthesis through heterologous
expression. These three enzymes generate a 24-carbon poly--ketone chain (Zhan et al. 2008).
WsaA, B and C are expected to create a nascent tridecaketide chain that contains 26 carbons.
While we have not expressed these enzymes in a heterologous host, a gene disruption was
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conducted for wsaA. Our results showed that disruption of wsaA abolished the production of 15, indicating that this enzyme is essential for the assembly of the core tridecaketide structure.
The nascent poly--ketone chain is highly reactive and is supposed to be cyclized by
associated aromatase and cyclases immediately. However, unlike pradimicins and benastatins,
the structures of 1-5 lack the 11-OH. This suggested that the 26-carbon poly--ketone
intermediate is reduced at C-11. There are three putative ketoreductase genes in the wsa gene
cluster, including wsaG, wsaV and wsaT. One of these ketoreductases is supposed to catalyze
the reduction. The corresponding hydroxyl group at C-11 will be eliminated by dehydration
during the cyclization and aromatization of ring A. The pradimicin biosynthetic gene cluster
contains an aromatase (PdmD) and two cyclases (PdmK and PdmL). PdmD closes rings A and
B of pradimicin A, and PdmK and PdmL are involved in the closure of rings C-E. In this work,
we found that the wsa biosynthetic gene cluster also contains the corresponding genes, including
the putative aromatase gene wsaD and cyclase genes wsaE and wsaF. However, there is an
additional cyclase gene, wsaW, in this gene cluster. We propose that this gene might be involved
in the closure of ring F of 2-5.
Monooxygenases are commonly found in aromatic polyketide biosynthesis and
contribute to the structural diversity of natural products. They can catalyze a series of reactions
such as hydroxylation and oxidation. Monooxygenases have been reported to have a role in
fidelity control during aromatic polyketide biosynthesis (Qin et al. 2019). In addition, these
enzymes are known to work with other tailoring enzymes such as cyclases synergistically. For
instance, PdmH is the ring B monooxygenase to form the quinone structure in pradimicins. This
enzyme works with two cyclases, PdmK and PdmL, to close rings C-E to form the core
pentangular structure of pradimicins (Zhan et al. 2008). While 2-5 have six rings, we propose
that 1 is their precursor with a pentangular structure. There is a putative monooxygenase,
WsaO3, in the wsa gene cluster. Its amino acid sequence shares 58% identity and 73% similarity
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with that of PdmH. Therefore, it was proposed to have a similar function and be responsible for
ring B quinone formation by working with two cyclases to form the pentangular structure of 1.
There are six additional monooxygenases in this gene cluster. Some of them are proposed to
catalyze the hydroxylation reactions such at C-6 and C-12. Methyltransferases are also common
modifying enzymes in natural product biosynthetic pathways. These enzymes introduce methyl
groups to various atoms such as C, O, S and N. Correspondingly, there are different methyl
transferases such as C-methyltransferases, O-methyltransferases, S-methyltransferases and Nmethyltransferases (Pavkov-Keller et al. 2017). There are two putative O-methyltransferase
genes (wsaM1 and wsaM2) in the wsa biosynthetic gene cluster. The structure of 1-4 contains
a OCH3 group at C-17, while the new compound 5 has an additional methoxy group at C-13.
Therefore, WsaM1 and WsaM2 are believed to introduce the two methyl groups to the 17-OH
and 13-OH, respectively.
The wsa gene cluster in Table 2 contains 38 open reading frames and it is likely some
of these genes just sit in the gene cluster but are not involved in the biosynthesis of 1-5. It is
also possible that the formation of certain minor compounds, such as 3, the acetylated derivative
of 2, requires the action of an enzyme not within this gene cluster. In summary, this study
discovered a new tridecaketide natural product, determined the configuration of C-19 of 1-5,
and reported the gene cluster responsible for the assembly of this group of natural products.
Therefore, this work provides valuable information for further understanding and engineering
of this biosynthetic pathway to generate new compounds for screening of novel ECE inhibitors.
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Table 1

1

H (300 MHz) and 13C (75 MHz) NMR data for 5 in DMSO-d6.

Position
1
2
3
3-OH
4
5
6
6-OH
7

δH

δC
170.5
107.5
162.1

11.72 (1H, s)
118.1
127.9
156.4
13.78 (1H, s)
115.2

25

8
9
10
11
12
12-OH
13
13-OCH3
14
15
16
17
17-OCH3
18
19
20
21
22
23
24
25
26

Table 2

7.93 (1H, d, 8.6)
7.28 (1H, d, 8.6)

188.0
125.0
125.9
121.3
159.0

10.96 (1H, s)
3.86 (3H, s)

3.93 (3H, s)
5.18 (1H, brs)
2.95 (1H, m)
2.71 (1H, m)
6.88 (1H, s)
3.05 (1H, m)
2.92 (1H, m)
4.88 (1H, m)
1.45 (3H, d, 6.2)

147.5
61.3
129.4
182.4
122.8
149.9
63.7
143.9
59.4
38.2
146.3
119.7
140.9
34.0
76.7
20.8

Putative functions of the genes in the wsa gene cluster.

Gene

Size
(aa)

wsaR1

263

wsaO1

408

TetR family transcriptional
regulator
monooxygenase

wsaU1

102

Hypothetical protein

wsaO2
wsaH5
wsaW
wsaV
wsaO3
wsaT

151
285
126
245
104
246

wsaS

562

Monooxygenase
Flavin-dependent oxidoreductase
Cyclase
Ketoreductase
Monooxygenase
Ketoreductase
NAD(P)/FAD-dependent
oxidoreductase

Putative function

Homolog/GenBank accession no.

Identity/
similarity

AcnR [Streptomyces costaricanus]/QAR15125

64/71

FlsP [Micromonospora rosaria]/ALJ99865
Hypothetical protein [Streptosporangium
minutum]/WP_086575026
Hex33 [Streptosporangium sp. FXJ7.131]/AMK51290
Hex32 [Streptosporangium sp. FXJ7.131]/AMK51289
Cyclase [Streptomyces sp. CNZ279]/WP_099879640
Hex30 [Streptosporangium sp. FXJ7.131]/AMK51287
PdmH [Actinomadura hibisca]/ABM21754
SimJ2 [Streptomyces antibioticus]/AAG34189

52/65

Hex28 [Streptosporangium sp. FXJ7.131]/AMK51285

98/99

26

93/96
99/99
99/98
76/85
99/99
58/73
57/75

wsaQ
wsaF
wsaE
wsaA
wsaB
wsaC
wasD
wsaO4
wsaG
wsaH1

294
108
150
422
406
86
160
157
243
541

wsaR2

232

wsaU2
wsaI
wsaU3

508
446
366

wsaJ

470

wsaH2
wsaH3
wsaO5
wsaM1
wsaK
wsaM2
wsaL
wsaN
wsaP
wsaH4
wsaO6
wsaO7

333
285
415
337
281
344
64
619
199
490
118
104

wsaR3

621

NAD(P)-dependent oxidoreductase
Cyclase
Cyclase
Ketosynthase
Chain length factor
Acyl carrier protein
Aromatase
Monooxygenase
Ketoreductase
FAD-dependent oxidoreductase
TenA family transcriptional
regulator
Hypothetical protein
Sodium:proton exchanger
Hypothetical protein
NAD(P)/FAD-dependent
oxidoreductase or halogenase
Flavin-dependent oxidoreductase
Flavin-dependent oxidoreductase
Monooxygenase
Methyltransferase
NAD(P)H-binding protein
Methyltransferase
Ferredoxin
Asparagine synthetase
Nitroreductase
FAD-dependent oxidoreductase
Monooxygenase
Monooxygenase
SARP family transcriptional
regulator

Hex27 [Streptosporangium sp. FXJ7.131]/AMK51284
BenE [Streptomyces sp. A2991200]/CAM58796
PdmL [Actinomadura hibisca]/ABK58685
PdmA [Actinomadura hibisca]/ABM21747
PdmB [Actinomadura hibisca]/ABM21748
PdmC [Actinomadura hibisca]/ABM21749
RubF [Streptomyces collinus]/AAG03070
Hex20 [Streptosporangium sp. FXJ7.131]/AMK51277
PdmG [Actinomadura hibisca]/ABM21753.1
TcmG [Streptomyces lydicus]/AJT61730

98/98
62/76
60/73
77/86
67/75
56/70
72/79
99/99
56/74
70/80

Hex17 [Streptosporangium sp. FXJ7.131]/AMK51274

98/98

Hex16 [Streptosporangium sp. FXJ7.131]/AMK51273
DacR3 [Dactylosporangium sp. SC14051]/AFU65890
Hex14 [Streptosporangium sp. FXJ7.131]/AMK51271

99/99
62/76
95/96

Hex13 [Streptosporangium sp. FXJ7.131]/AMK51270

98/98

Hex12 [Streptosporangium sp. FXJ7.131]/AMK51269
Hex11 [Streptosporangium sp. FXJ7.131]/AMK51268
Hex10 [Streptosporangium sp. FXJ7.131]/AMK51267
TcmO [Streptomyces lydicus]/AJT61734
Hex8 [Streptosporangium sp. FXJ7.131]/AMK51265
Hex7 [Streptosporangium sp. FXJ7.131]/AMK51264
Ferredoxin [Actinomadura sp. J1-007]/WP_164717208
OxyD [Streptomyces rimosus]/AAZ78328
Hex5 [Streptosporangium sp. FXJ7.131]/AMK51262
Hex4 [Streptosporangium sp. FXJ7.131]/AMK51261
Hex3 [Streptosporangium sp. FXJ7.131]/AMK51260
GrhU [Actinoplanes sp. N902-109]/AGL16614

98/98
99/99
98/99
68/80
99/99
96/97
76/88
52/66
99/99
99/100
96/96
62/70

Hex1 [Streptosporangium sp. FXJ7.131]/AMK51258

99/99

Figure legends

Fig. 1 Structures of 1-5 from S. roseum No. 79089.
Fig. 2 LC-MS analysis of the production of 1-5 by S. roseum No. 79089. a HPLC traces (460
nm) of the cultures of wild type (i) and wsaA-disrupted mutant (ii) strains of S. roseum No.

27

79089. b ESI-MS (-) spectrum of 1. c ESI-MS (-) spectrum of 2. d ESI-MS (-) spectrum of 3. e
ESI-MS (-) spectrum of 4. f ESI-MS (-) spectrum of 5.
Fig. 3 Key HMBC correlations for 5.
Fig. 4 Δ (S-R) values for the MTPA esters of 2.
Fig. 5 The wsa biosynthetic gene cluster (a) and proposed biosynthetic pathways (b) of 1-5.
Fig. 6 Gene disruption of wsaA in S. roseum No. 79089. a The strategy to disrupt wsaA in S.
roseum No. 79089 through single crossover recombination. b PCR verification of the wsaAdisrupted mutant. M: 1 kb plus DNA ladder; 1: mutant; 2: wild type.
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